About Synspira Therapeutics
Synspira Therapeutics is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis and other rare diseases where there is a high unmet treatment need.
At Synspira, we are focused on improving how these diseases are treated, initially through the development of an innovative, new class of proprietary inhaled glycopolymer-based therapeutics that target progressive pulmonary diseases or other life-threatening pulmonary conditions.
We know that the people who are living with these challenging diseases are not defined by their conditions. We are dedicated to developing novel and innovative therapies that change the way these diseases are treated so that patients can live fuller lives.
Synspira Therapeutics is a privately held company headquartered in Framingham, MA.
Our lead product, SNSP113, is a first-of-its-kind product with a broad spectrum mechanism of action. SNSP113 is designed to target the underlying cascade of events that lead to progressive pulmonary disease or other life-threatening pulmonary conditions.
At Synspira, we are inspired by patients and are driven to make a difference.